Larimar Therapeutics Q4 net loss widens on higher R&D costs

Overview

• US biotech firm's Q4 net loss widened, driven by higher R&D expenses for nomlabofusp

• Company completed $115 mln public offering in Feb 2026, extending cash runway into Q2 2027

• FDA granted Breakthrough Therapy Designation for nomlabofusp in adults and children with FA

Outlook

• Larimar plans to report topline open label study data in Q2 2026

• Company expects to initiate screening for global Phase 3 study in Q2 2026

• Larimar targets BLA submission seeking accelerated approval in June 2026; U.S. launch first-half 2027, if approved

Result Drivers

• NOMLABOFUSP MANUFACTURING COSTS - Higher Q4 R&D expenses were mainly due to increased nomlabofusp manufacturing costs, including process qualification and scale up activities

• CLINICAL AND REGULATORY SPENDING - Additional increases came from higher costs for ongoing clinical studies, consulting fees for quality, clinical, and regulatory activities, and personnel expenses

• LOWER INTEREST INCOME - Decrease in other income was mainly due to lower interest yields and lower average investable cash balances

Company press release: ID:nGNXbPqYrY

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 11 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy."

• Wall Street's median 12-month price target for Larimar Therapeutics Inc is $16.00, about 272.1% above its March 18 closing price of $4.30

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.